PMID- 35920966
OWN - NLM
STAT- MEDLINE
DCOM- 20221110
LR  - 20240213
IS  - 1873-4626 (Electronic)
IS  - 1091-255X (Linking)
VI  - 26
IP  - 11
DP  - 2022 Nov
TI  - Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally 
      Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study.
PG  - 2292-2300
LID - 10.1007/s11605-022-05421-x [doi]
AB  - BACKGROUND: Unresectable hepatocellular carcinoma (HCC) has a poor prognosis. We 
      aimed to evaluate the efficacy and safety of hepatic arterial infusion 
      chemotherapy (HAIC) for locally advanced HCC compared to transcatheter arterial 
      chemoembolization (TACE). METHODS: A propensity score-matched cohort study was 
      performed in patients with locally advanced HCC with >/= 4 tumors or portal vein 
      tumor thrombosis (PVTT) who underwent either HAIC using oxaliplatin plus 
      raltitrexed or TACE at three institutions between June 2015 and December 2021. 
      Overall survival (OS), progression-free survival (PFS), objective response rates 
      (ORR), and adverse events (AEs) were compared between the groups. RESULTS: After 
      propensity score matching, 62 pairs of patients were evaluated. The HAIC group 
      had longer OS (15.0 [95% CI: 12.1-17.9] vs. 9.0 [95% CI: 5.1-12.9] months; 
      P = 0.034), better PFS (6.7 [95% CI: 5.1-8.3] vs. 4.0 [95% CI: 2.6-5.4] months; 
      P = 0.020), and a higher ORR (RECIST 1.1: 54.8% vs. 11.3%; P < 0.001) than the 
      TACE group in the intention-to-treat population. Compared with the TACE group, 
      Grade 1-2 nausea and vomiting occurred significantly more frequently in the HAIC 
      group. CONCLUSION: Compared to TACE, HAIC significantly increased the ORR of 
      locally advanced HCC with multiple tumors or portal invasion and prolonged 
      survival without causing a significant increase in severe AEs.
CI  - (c) 2022. The Society for Surgery of the Alimentary Tract.
FAU - Chen, Shiguang
AU  - Chen S
AD  - Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma 
      Road, Fuzhou, 350014, China.
FAU - Yuan, Bo
AU  - Yuan B
AD  - Xuzhou Central Hospital, Xuzhou, China.
FAU - Yu, Wenchang
AU  - Yu W
AD  - Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma 
      Road, Fuzhou, 350014, China.
FAU - Wang, Xiaolong
AU  - Wang X
AD  - Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma 
      Road, Fuzhou, 350014, China.
FAU - He, Chengjian
AU  - He C
AD  - The Second Military Medical University Affiliated Eastern Hepatobiliary Hospital, 
      Shanghai, China.
FAU - Chen, Chuanben
AU  - Chen C
AD  - Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma 
      Road, Fuzhou, 350014, China. ccb@fjmu.edu.com.
LA  - eng
GR  - 2019Y0060/Natural Science Foundation of Fujian Province/
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220803
PL  - Netherlands
TA  - J Gastrointest Surg
JT  - Journal of gastrointestinal surgery : official journal of the Society for Surgery 
      of the Alimentary Tract
JID - 9706084
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/therapy/pathology
MH  - *Chemoembolization, Therapeutic
MH  - *Liver Neoplasms/pathology
MH  - Retrospective Studies
MH  - Cohort Studies
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Hepatic Artery/pathology
MH  - *Venous Thrombosis/etiology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Hepatic arterial Infusion Chemotherapy
OT  - Hepatocellular Carcinoma
OT  - Oxaliplatin
OT  - Raltitrexed
OT  - Transcatheter Arterial Chemoembolization
EDAT- 2022/08/04 06:00
MHDA- 2022/11/11 06:00
CRDT- 2022/08/03 11:19
PHST- 2022/03/28 00:00 [received]
PHST- 2022/07/16 00:00 [accepted]
PHST- 2022/08/04 06:00 [pubmed]
PHST- 2022/11/11 06:00 [medline]
PHST- 2022/08/03 11:19 [entrez]
AID - S1091-255X(23)01489-0 [pii]
AID - 10.1007/s11605-022-05421-x [doi]
PST - ppublish
SO  - J Gastrointest Surg. 2022 Nov;26(11):2292-2300. doi: 10.1007/s11605-022-05421-x. 
      Epub 2022 Aug 3.